Joint with: Cancer Immunotherapy: Clinical Lessons to New Modalities
Immune Cell Therapies: Advances in Cancer and Autoimmune Disease
Mar 16–19, 2025 | Fairmont Banff Springs, Banff, AB, Canada
Scientific Organizers:
Katy Rezvani, Nathan Singh and Stephan Mielke
In Person
On Demand
Mar 16–19, 2025 | Fairmont Banff Springs, Banff, AB, Canada
Scientific Organizers:
Katy Rezvani, Nathan Singh and Stephan Mielke
Available Formats:
Supported by:
In Person
On Demand
Available Formats: = In Person = On Demand
Merchandise Options
Registration Options
Sunday, March 16, 2025
Fundraising
Booking Function
Registration
4:00–8:00 PM
Van Horne Foyer
Welcome Mixer
6:00–8:00 PM
Van Horne Foyer
Monday, March 17, 2025
Breakfast
7:00–8:00 AM
Mezzanine 2
Welcome and Keynote Session (Joint)
8:00–9:30 AM
Van Horne Ballroom
Carl H. June, University of Pennsylvania
Cell Therapies: Current State-of the Art
Cell Therapies: Current State-of the Art
Ton N. Schumacher, Netherlands Cancer Institute
Dissecting T Cell Recognition of Cancer
Dissecting T Cell Recognition of Cancer
Coffee Break
9:30–9:50 AM
Van Horne Foyer
Award Recipient Acknowledgement
9:50–9:55 AM
Van Horne Ballroom
Overcoming Challenges in Immune and Cell Therapy: Insights into Mechanisms of Failure and Solutions (Joint)
9:55–12:00 PM
Van Horne Ballroom
Nathan Singh, Washington University School of Medicine
Genomic Regulation of CAR-Driven T Cell Dysfunction
Genomic Regulation of CAR-Driven T Cell Dysfunction
Shannon J Turley, Genentech, Inc.
CAF Targeting
CAF Targeting
Anna Christina Obenauf, Research Institute of Molecular Pathology
Rational Combination of Therapies to Stimulate the APC Compartment
Rational Combination of Therapies to Stimulate the APC Compartment
May Daher, MD Anderson Cancer Center
Metabolic Interventions to Enhance Adoptive Cellular Therapies
Metabolic Interventions to Enhance Adoptive Cellular Therapies
Poster Setup
12:00–1:00 PM
Mezzanine 2
On Own for Lunch
12:00–2:30 PM
Poster Viewing
1:00–10:00 PM
Mezzanine 2
Symposia Spotlight 1: Late-breaking research presentations selected from abstract submissions
2:30–4:30 PM
Van Horne B/C
Zachary Steinhart †, Gladstone-UCSF Institute of Genomic Immunology
Deciphering Natural and Synthetic Genetic Programs Governing Human T Cell Function with Combinatorial CRISPR Activation and Interference Screens
Deciphering Natural and Synthetic Genetic Programs Governing Human T Cell Function with Combinatorial CRISPR Activation and Interference Screens
Xinchen Wang, Waypoint Bio
In Vivo Spatial Pooled Screening Identifies CAR T Constructs with Superior Anti-Solid Tumor Efficacy and Safety
In Vivo Spatial Pooled Screening Identifies CAR T Constructs with Superior Anti-Solid Tumor Efficacy and Safety
Ju-Fang Chang, Washington University in St Louis
Generation of MHC-Independent T Cell Receptors Using Rational Protein Engineering
Generation of MHC-Independent T Cell Receptors Using Rational Protein Engineering
Reno Debets, Erasmus MC Cancer Institute
Human T Cell Receptors Equipped with Inducible Co-Stimulator Mediate Durable Anti-Tumor Activity
Human T Cell Receptors Equipped with Inducible Co-Stimulator Mediate Durable Anti-Tumor Activity
Hector Caballero Gonzalez, Cellply Srl
Single-Cell Profiling Reveals Functional Dynamics Of Adapter CAR-T Cells Targeting CD33+ Acute Myeloid Leukemia
Single-Cell Profiling Reveals Functional Dynamics Of Adapter CAR-T Cells Targeting CD33+ Acute Myeloid Leukemia
Jemma Larson, University of Minnesota
Striking a Balance: Human CAR19+ CD8-Itreg for Prevention of GVHD And Enhanced Anti-Leukemic Efficacy Without Systemic Toxicity
Striking a Balance: Human CAR19+ CD8-Itreg for Prevention of GVHD And Enhanced Anti-Leukemic Efficacy Without Systemic Toxicity
Yinghui Jane Huang †, University of Pennsylvania
Continuous Expression of TOX Safeguards Exhausted CD8 T Cell Epigenetic Fate
Continuous Expression of TOX Safeguards Exhausted CD8 T Cell Epigenetic Fate
Christoph T Ellebrecht †, University of Pennsylvania
Essential Genes of Human T Cell Tissue Residency Identified Through Genome-Wide CRISPR Screening in a Human Skin Xenograft Model
Essential Genes of Human T Cell Tissue Residency Identified Through Genome-Wide CRISPR Screening in a Human Skin Xenograft Model
Coffee Available
4:30–5:00 PM
Van Horne Foyer
Cell Therapies for Solid Tumors
5:00–7:00 PM
Van Horne B/C
Nicholas Vitanza, Seattle Children’s / University of Washington
Advancing Locoregional CAR T Cell Therapy for Pediatric CNS Tumors
Advancing Locoregional CAR T Cell Therapy for Pediatric CNS Tumors
Marcela V. Maus, Harvard Medical School
Driving Complex CAR-T into the Clinic – What, Why, and How
Driving Complex CAR-T into the Clinic – What, Why, and How
Andras Heczey, Baylor College of Medicine
Cytokine Armored GPC3-CAR T Cells for Patients with Solid Tumors
Cytokine Armored GPC3-CAR T Cells for Patients with Solid Tumors
Tori Yamamoto, Gladstone Institutes
Short Talk: In Vivo CRISPRa Screens Uncover Positive and Negative Regulators of T Cell Accumulation in the Immunocompetent Tumor Microenvironment
Short Talk: In Vivo CRISPRa Screens Uncover Positive and Negative Regulators of T Cell Accumulation in the Immunocompetent Tumor Microenvironment
Filippo Birocchi, MGH
Short Talk: Balancing Efficacy and Safety: Overcoming On-Target Off-Tumor Toxicity of Claudin18.2-Directed CAR-T Cells in Preclinical Models
Short Talk: Balancing Efficacy and Safety: Overcoming On-Target Off-Tumor Toxicity of Claudin18.2-Directed CAR-T Cells in Preclinical Models
Social Hour with Lite Bites
7:00–8:00 PM
Mezzanine 2
Posters
7:30–10:00 PM
Mezzanine 2
Tuesday, March 18, 2025
Breakfast
7:00–8:00 AM
Mezzanine 2
Diversity, Access and Pathways to Regulatory Approval
8:00–11:00 AM
Van Horne B/C
Stephan Mielke, Karolinska Institutet
CAR T Cells: A European Perspective
CAR T Cells: A European Perspective
Heather Lombardi, FDA HHS
Regulatory Considerations for Cell Therapies
Regulatory Considerations for Cell Therapies
Jen Chow, Chimeric Therapeutics
Commercially Conscious Development of Cell Therapies
Commercially Conscious Development of Cell Therapies
Rayne H. Rouce, Baylor College of Medicine
Improving Access to Cell Therapies
Improving Access to Cell Therapies
Coffee Break
9:00–9:20 AM
Van Horne Foyer
Poster Setup
11:00–1:00 PM
Mezzanine 2
On Own for Lunch
11:00–5:00 PM
Poster Viewing
1:00–10:00 PM
Mezzanine 2
Career Roundtable (Joint)
3:00–4:30 PM
Van Horne B/C
Coffee Available
4:30–5:00 PM
Van Horne Foyer
Cell Therapy for Autoimmune Diseases
5:00–7:00 PM
Van Horne B/C
Andreas Mackensen, University Hospital of Erlangen
CAR T Cells for B-cell mediated Autoimmune Disease
CAR T Cells for B-cell mediated Autoimmune Disease
Gwendolyn Binder, Cabaletta Bio
Clinical and Translational Development of Engineered T Cell Therapy for Autoimmune Disease
Clinical and Translational Development of Engineered T Cell Therapy for Autoimmune Disease
Megan K. Levings, University of British Columbia
CAR Tregs
CAR Tregs
Eleanor Chen, The University of British Columbia
Short Talk: Alloantigen-Specific CAR Tregs Mediate Islet Protection By Suppressing Islet Autoantigen-Specific T Cells
Short Talk: Alloantigen-Specific CAR Tregs Mediate Islet Protection By Suppressing Islet Autoantigen-Specific T Cells
Siddarth Chandrasekaran †, Notch Therapeutics
Short Talk: Potent B-Cell Depletion Using Off-The-Shelf Ipsc-Derived CD19 CAR-T Cells from Scalable Bioreactors
Short Talk: Potent B-Cell Depletion Using Off-The-Shelf Ipsc-Derived CD19 CAR-T Cells from Scalable Bioreactors
Social Hour with Lite Bites
7:00–8:00 PM
Mezzanine 2
Posters
7:30–10:00 PM
Mezzanine 2
Wednesday, March 19, 2025
Breakfast
7:00–8:00 AM
Mezzanine 2
Alternative Immune Effectors
8:00–11:00 AM
Van Horne B/C
Katy Rezvani, University of Texas MD Anderson Cancer Center
Engineering NK Cells for Cancer Immunotherapy
Engineering NK Cells for Cancer Immunotherapy
Michael Klichinsky, Carisma Therapeutics
CAR-M: Engineering Myeloid Cells ex vivo and in vivo for Cancer Immunotherapy
CAR-M: Engineering Myeloid Cells ex vivo and in vivo for Cancer Immunotherapy
Bob Valamehr, Fate Therapeutics
iPSCs for Cell Therapy
iPSCs for Cell Therapy
Jurgen Kuball, University Medical Center
Mastering Diversity of gdT Cells and the Receptors for Cancer Immune Therapies
Mastering Diversity of gdT Cells and the Receptors for Cancer Immune Therapies
Shelby Namen, Washington University in St. Louis
Short Talk: CAR Engineered Dcs Respond to Tumor in a Signaling Distinct Manner
Short Talk: CAR Engineered Dcs Respond to Tumor in a Signaling Distinct Manner
Yeara Jo, University of California, Berkeley
Short Talk: Elucidating Molecular Mechanisms of NK Cell Function from the Studies of NK Cell Desensitization and Exhaustion for Improved Anti-Cancer Therapies
Short Talk: Elucidating Molecular Mechanisms of NK Cell Function from the Studies of NK Cell Desensitization and Exhaustion for Improved Anti-Cancer Therapies
Coffee Break
9:00–9:20 AM
Van Horne Foyer
On Own for Lunch
11:00–2:30 PM
Symposia Spotlight 2: Late-breaking research presentations selected from abstract submissions
2:30–4:30 PM
Van Horne B/C
Maxwell Foisey, University of California San Francisco
Hybrid-R: Overcoming Limitations in T Cell Therapy With A Single Synthetic Receptor
Hybrid-R: Overcoming Limitations in T Cell Therapy With A Single Synthetic Receptor
Yuxiao Wang, Myeloid Therapeutics
Innate Immune Receptor-Based Cars For In Vivo Programming of Myeloid Cells to Combat Solid Tumors
Innate Immune Receptor-Based Cars For In Vivo Programming of Myeloid Cells to Combat Solid Tumors
Zoila I Fernandez †, Stanford University
Myeloid Cell States as Regulators Of CAR-T Cell Function
Myeloid Cell States as Regulators Of CAR-T Cell Function
Alexander Kim, Washington University School of Medicine
Amyloid Plaque Targeting Chimeric Antigen Receptor Macrophages for Alzheimer’s Disease Therapy
Amyloid Plaque Targeting Chimeric Antigen Receptor Macrophages for Alzheimer’s Disease Therapy
Clara Soulard, CHU Sainte Justine
Exploring the Potential Of CAR-Engineered Hscs for Treating B-Cell Acute Lymphoblastic Leukemia
Exploring the Potential Of CAR-Engineered Hscs for Treating B-Cell Acute Lymphoblastic Leukemia
Kevin Salim, BC Children's Hospital Research Institute/University of British Columbia
Differentiation of Human CD4+ T Cells from Pluripotent Stem Cells
Differentiation of Human CD4+ T Cells from Pluripotent Stem Cells
Hind Rafei, The University of Texas MD Anderson Cancer Center
CREM is a Regulatory Checkpoint of CAR And IL-15 Signaling in NK Cells
CREM is a Regulatory Checkpoint of CAR And IL-15 Signaling in NK Cells
Ritu Bohat †, MD Anderson Cancer Center
Enhancing CAR-NK Potency and Persistence with Myd88/CD40 Costimulation
Enhancing CAR-NK Potency and Persistence with Myd88/CD40 Costimulation
Coffee Available
4:30–5:00 PM
Van Horne Foyer
Engineering in Cancer Immunotherapy to Enhance Efficacy (Joint)
5:00–6:30 PM
Van Horne Ballroom
Jaehyuk Choi, Northwestern University
Talk Title to be Announced
Talk Title to be Announced
Rosandra Natasha Kaplan, NCI, National Institutes of Health
Engineering of Myeloid Cells
Engineering of Myeloid Cells
Julia Carnevale, University of California, San Francisco
CRISPR-Based T Cell Editing to Enhance Cell Therapy
CRISPR-Based T Cell Editing to Enhance Cell Therapy
Meeting Wrap-Up: Outcomes and Future Directions (Organizers) (Joint)
6:30–7:00 PM
Van Horne Ballroom
Social Hour with Lite Bites
7:00–8:00 PM
Mezzanine 2
Entertainment
8:00–11:00 PM
Cash Bar
8:00–11:00 PM
Thursday, March 20, 2025
Departure
12:00–11:59 PM
Subscribe for Updates